Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Hepatocellular 66Carcinoma, Renal Cell 38Liver Neoplasms 20Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 16Neoplasms 15Breast Neoplasms 15Melanoma 13Thyroid Neoplasms 10Leukemia, Myeloid, Acute 10Sarcoma 9Lung Neoplasms 8Kidney Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 7Urinary Bladder Neoplasms 6Pancreatic Neoplasms 6Glioblastoma 6Brain Neoplasms 6Colorectal Neoplasms 5Carcinoma, Medullary 5Thyroid Carcinoma, Anaplastic 4Stomach Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Gallbladder Neoplasms 4Colonic Neoplasms 4Breast Neoplasms, Male 4Thyroid Diseases 3Thyroid Cancer, Papillary 3

Interventions

Cyclophosphamide 17Trastuzumab 16Paclitaxel 15Doxorubicin 11Docetaxel 10Radiotherapy 9Carboplatin 9Capecitabine 9Bevacizumab 8Lapatinib 7Taxes 6Tamoxifen 6Gemcitabine 5Filgrastim 5Chemotherapy, Adjuvant 5sargramostim 4Sorafenib 4Radiation 4Neoadjuvant Therapy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Vinorelbine 3Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3Erlotinib Hydrochloride 3Anastrozole 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms, Male × Sorafenib × Clear all
NCT00096434 2024-03-07

Sorafenib in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00622466 2020-10-19

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

University of Texas Southwestern Medical Center

Phase 2 Terminated
20 enrolled 8 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00499525 2019-05-03

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

Northwestern University

Phase 2 Unknown
180 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00722072 2018-02-26

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

OHSU Knight Cancer Institute

Phase 2 Terminated
12 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡